Cargando…
Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study
BACKGROUND: Hepatitis B virus (HBV) infection is a serious global health problem that is associated with huge social and economic costs. Early antiviral drugs, such as interferon-α2b, peginterferon-α2a, lamivudine, and adefovir, all have their limitations (such as low responses or safety concerns) i...
Autores principales: | Liang, Jian, Jiang, Man Jun, Deng, Xin, Xiao Zhou, Xiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759781/ https://www.ncbi.nlm.nih.gov/pubmed/24032045 http://dx.doi.org/10.5812/hepatmon.7862 |
Ejemplares similares
-
Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels
por: Shi, Hong, et al.
Publicado: (2017) -
52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B
por: Piratvisuth, Teerha, et al.
Publicado: (2013) -
Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B
por: Zhu, Xiao-Feng, et al.
Publicado: (2011) -
Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study
por: Yang, Xiaoling, et al.
Publicado: (2017) -
Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis
por: Banerjee, S., et al.
Publicado: (2016)